{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:14:56Z","timestamp":1789564496408,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022600","name":"Taipei Municipal Wan-Fang Hospital","doi-asserted-by":"publisher","award":["112-wf-eva-05"],"award-info":[{"award-number":["112-wf-eva-05"]}],"id":[{"id":"10.13039\/501100022600","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jmii.2024.04.008","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T03:13:56Z","timestamp":1714101236000},"page":"617-628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mitigating treatment failure of pulmonary pre-extensively drug-resistant tuberculosis: The role of new and repurposed drugs"],"prefix":"10.1016","volume":"57","author":[{"given":"Yi-Wen","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chih","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Bin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8073-4693","authenticated-orcid":false,"given":"Jen-Jyh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0837-8414","authenticated-orcid":false,"given":"Chou-Jui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Tien","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-3044","authenticated-orcid":false,"given":"Chih-Hsin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9291-2490","authenticated-orcid":false,"given":"Chen-Yuan","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jmii.2024.04.008_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5588\/ijtld.17.0660","article-title":"Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs","volume":"22","author":"Van Deun","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jmii.2024.04.008_bib2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1183\/09031936.00134712","article-title":"Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes","volume":"42","author":"Falzon","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2024.04.008_bib3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"Pym","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2024.04.008_bib4","article-title":"Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis","volume":"49","author":"Guglielmetti","year":"2017","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jmii.2024.04.008_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01105-2017","article-title":"Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens","volume":"50","author":"Kuksa","year":"2017","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jmii.2024.04.008_bib6","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S1473-3099(18)30100-2","article-title":"Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study","volume":"18","author":"Ferlazzo","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2024.04.008_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12941-016-0156-y","article-title":"Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis","volume":"15","author":"Agyeman","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jmii.2024.04.008_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1183\/09031936.00145014","article-title":"Linezolid to treat MDR-\/XDR-tuberculosis: available evidence and future scenarios.","volume":"45","author":"Sotgiu","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2024.04.008_bib9","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1183\/13993003.02146-2015","article-title":"Effectiveness and safety of meropenem\/clavulanate-containing regimens in the treatment of MDR- and XDR-TB","volume":"47","author":"Tiberi","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2024.04.008_bib10","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1183\/09031936.00124312","article-title":"Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-\/XDR-TB","volume":"41","author":"De Lorenzo","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2024.04.008_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02445-2016","article-title":"Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil","volume":"49","author":"Dalcolmo","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2024.04.008_bib12","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/civ027","article-title":"Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China","volume":"60","author":"Tang","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2024.04.008_bib13","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang\u2019wa","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2024.04.008_bib14","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1183\/09031936.06.00125705","article-title":"Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study","volume":"28","author":"Chiang","year":"2006","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jmii.2024.04.008_bib15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/cid\/ciy066","article-title":"Treatment outcomes of multidrug-resistant tuberculosis in Taiwan: tackling loss to follow-up","volume":"67","author":"Yu","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2024.04.008_bib16","article-title":"Impact of universal drug susceptibility testing and effective management of multidrug-resistant tuberculosis in Taiwan","volume":"14","author":"Lee","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2024.04.008_bib17","first-page":"1","article-title":"Definitions and reporting framework for tuberculosis - 2013 revision","volume":"2","year":"2013","journal-title":"World Health Organization Document"},{"key":"10.1016\/j.jmii.2024.04.008_bib18","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/1791013a0","article-title":"A new series of phenazines (rimino-compounds) with high antituberculosis activity","volume":"179","author":"Barry","year":"1957","journal-title":"Nature"},{"key":"10.1016\/j.jmii.2024.04.008_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115539","article-title":"Clofazimine: a journey of a drug","volume":"167","author":"Xu","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jmii.2024.04.008_bib20","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jmii.2024.04.008_bib21","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis","volume":"380","author":"Nunn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2024.04.008_bib22","first-page":"87","article-title":"Clinical update on linezolid in the treatment of Gram-positive bacterial infections","volume":"5","author":"Ager","year":"2012","journal-title":"Infect Drug Resist"},{"issue":"4","key":"10.1016\/j.jmii.2024.04.008_bib23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41579-018-0147-4","article-title":"Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research","volume":"17","author":"Turner","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jmii.2024.04.008_bib24","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1128\/AAC.47.1.416-417.2003","article-title":"In\u00a0vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs","volume":"47","author":"Alcal\u00e1","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2024.04.008_bib25","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2024.04.008_bib26","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.jmii.2024.04.008_bib27","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: past, present, and future","volume":"55","author":"Papp-Wallace","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"5918","key":"10.1016\/j.jmii.2024.04.008_bib28","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1126\/science.1167498","article-title":"Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis","volume":"323","author":"Hugonnet","year":"2009","journal-title":"Science."},{"key":"10.1016\/j.jmii.2024.04.008_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01489-18","article-title":"Evaluation of carbapenems for treatment of multi- and extensively drug-resistant Mycobacterium tuberculosis","volume":"63","author":"van Rijn","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2024.04.008_bib30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science."},{"key":"10.1016\/j.jmii.2024.04.008_bib31","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1128\/AAC.02243-12","article-title":"Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis","volume":"57","author":"Diacon","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2024.04.008_bib32","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.200807-1152OC","article-title":"Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis","volume":"180","author":"Ibrahim","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jmii.2024.04.008_bib33","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and bedaquiline. The authors reply. (Correspondence)","volume":"371","author":"Diacon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2024.04.008_bib34","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02078-5","article-title":"Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial","volume":"400","author":"Goodall","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2024.04.008_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in\u00a0vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.jmii.2024.04.008_bib36","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for multidrug-resistant pulmonary tuberculosis","volume":"366","author":"Gler","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2024.04.008_bib37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","article-title":"Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial","volume":"7","author":"von Groote-Biddlingmaier","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jmii.2024.04.008_bib38","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2024.04.008_bib39","first-page":"1","article-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","volume":"3","year":"2019","journal-title":"World Health Organization Document"},{"key":"10.1016\/j.jmii.2024.04.008_bib40","series-title":"WHO consolidated guidelines on tuberculosis. Module 4: drug-resistant tuberculosis treatment","year":"2022"},{"key":"10.1016\/j.jmii.2024.04.008_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165222","article-title":"Population-based drug resistance surveillance of multidrug-resistant tuberculosis in Taiwan, 2007-2014","volume":"11","author":"Chuang","year":"2016","journal-title":"PLoS One"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118224000768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118224000768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T02:23:53Z","timestamp":1731810233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118224000768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1684118224000768"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2024.04.008","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitigating treatment failure of pulmonary pre-extensively drug-resistant tuberculosis: The role of new and repurposed drugs","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2024.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}